Main public logs
Combined display of all available logs of CAMIH. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 08:57, 11 July 2024 MKraft talk contribs created page Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies (Created page with "{{Reference |Reference=Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies }} {{Study Note |Study Note=This is the second study of Fallon et al. (2017): Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, rando...")
- 08:54, 11 July 2024 MKraft talk contribs created page Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies (Created page with "{{Reference |Reference=Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies }} {{Study Note |Study Note=This study is the first study of Fallon et al. (2017): Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind,...")
- 08:48, 11 July 2024 MKraft talk contribs created page Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies (Created page with "{{Publication |Title=Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies |Topic=Cannabinoids |Author=Fallon, M T; Lux, E A; McQuade, R; Rossetti, S; Sanchez, R; Sun, W; Wright, S; Lichtman, A H; Kornyeyeva, E |Year=2017 |Journal=British Journal of Pain |DOI=https://doi.org/10.1177/2049463717710042 |Authors Abstract=Backgrou...")
- 10:06, 10 July 2024 MKraft talk contribs created page Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study (Created page with "{{Reference |Reference=Publication: Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study }} {{Study Note |Study Note=? }} =Brief summary= The study included 469 patients with different types of cancer. Randomly divided into 3 groups, one group received megestrol acetate, one group received dronabinol and one group received both drugs. After an estimated 2-3 months, there was an advanta...")
- 09:50, 10 July 2024 MKraft talk contribs created page Publication: Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study (Created page with "{{Publication |Title=Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study |Topic=Cannabinoids |Author=Jatoi, A; Windschitl, H E; Loprinzi, C L; Sloan, J A; Dakhil, S R; Mailliard, J A; Pundaleeka, S; Kardinal, C G; Fitch, T R; Krook, J E; Novotny, P J; Christensen, B |Year=2002 |Journal=Journal of Clinical Oncology |DOI=https://doi.org/10.1200/JCO.2002.20.2.567 |Authors Abstract=Purpos...")
- 05:15, 8 July 2024 MKraft talk contribs created page Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial (Created page with "{{Reference |Reference=Publication: Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial }} {{Study Note |Study Note=? }} =Brief summary= The study included 81 patients with different types of cancer and a history of nausea and vomiting due to chemotherapy. They were randomly divided into 2 groups, one group received THC and CBD daily and the other group a placebo. After one cycl...")
- 04:59, 8 July 2024 MKraft talk contribs created page Publication: Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial (Created page with "{{Publication |Title=Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial |Topic=Cannabinoids |Author=Grimison, P; Mersiades, A; Kirby, A; Lintzeris, N; Morton, R; Haber, P; Olver, I; Walsh, A; McGregor, I; Cheung, Y; Tognela, A; Hahn, C; Briscoe, K; Aghmesheh, M; Fox, P; Abdi, E; Clarke, S; Della-Fiorentina, S; Shannon, J; Gedye, C; Begbie, S; Simes, J; Stockler, M |Year=2020 |J...")
- 11:05, 1 July 2024 MKraft talk contribs created page Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial (Created page with "{{Reference |Reference=Publication: Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial }} =Brief summary= In the study, 56 patients with head and neck tumors were randomly divided into 2 groups, one of which received nabilone (synthetic THC) every day and the other a placebo. All patients received radiotherapy or a combination of radiotherapy and chemotherapy for 7 weeks. At...")
- 11:03, 1 July 2024 MKraft talk contribs created page Publication: Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial (Created page with "{{Publication |Title=Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial |Topic=Cannabinoids |Author=Côté, M; Trudel, M; Wang, C; Fortin, A |Year=2016 |Journal=Annals of Otology, Rhinology & Laryngology |DOI=https://doi.org/10.1177/0003489415612801 |Authors Abstract=Objectives: Patients treated for head and neck carcinomas experience a significant deterioration of their qua...")
- 09:36, 27 June 2024 MKraft talk contribs created page Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain (Created page with "{{Reference |Reference=Publication: Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain }} =Brief summary= The study included 397 patients with various types of advanced cancer. Randomly divided into 2 groups, one group received nabiximol (THC and CBD) and one group a placebo for 5 weeks. The daily dose varied from person to person, depending on...")
- 09:34, 27 June 2024 MKraft talk contribs created page Publication: Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain (Created page with "{{Publication |Title=Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain |Topic=Cannabinoids |Author=Lichtman, A H; Lux, E A; McQuade, R; Rossetti, S; Sanchez, R; Sun, W; Wright, S; Kornyeyeva, E; Fallon, M T |Year=2018 |Journal=Journal of Pain and Symptom Management |DOI=https://doi.org/10.1016/j.jpainsymman.2017.09.001 |Authors Abstract=Context...")
- 09:30, 26 June 2024 MKraft talk contribs created page Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial (Created page with "{{Reference |Reference=Publication: Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial }} =Brief summary= In this study, the effect of nabiximol, a cannabis-containing oral spray, on the personal perception of pain in patients with various advanced cancers and moderate to severe tumor pain was investigated as a function of dose. The study compared four different groups, namely three diffe...")
- 09:22, 26 June 2024 MKraft talk contribs created page Publication: Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial (Created page with "{{Publication |Title=Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial |Topic=Cannabinoids |Author=Portenoy, K; Ganae-Motan, E D; Allende, S; Yanagihara, R; Shaiova, L; Weinstein, S; McQuade, R; Wright, S; Fallon, M T |Year=2012 |Journal=The Journal of Pain |DOI=https://doi.org/10.1016/j.jpain.2012.01.003 |Authors Abstract=Patients with advanced cancer who have pain that responds poorly...")
- 10:05, 24 June 2024 MKraft talk contribs created page Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain (Created page with "{{Reference |Reference=Publication: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain }} =Brief summary= In this study, 177 patients with advanced cancer were randomly divided into 3 groups. One group received THC and CBD for 2 weeks, the other group only THC and the last group a placebo. The daily dose varied from pe...")
- 09:59, 24 June 2024 MKraft talk contribs created page Publication: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain (Created page with "{{Publication |Title=Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain |Topic=Cannabinoids |Author=Johnson, J R; Burnell-Nugent, M; Lossignol, D; Ganae-Motan, E D; Potts, R; Fallon, M T |Year=2010 |Journal=Journal of pain and symptom management |DOI=https://doi.org/10.1016/j.jpainsymman.2009.06.008 |Authors Abstract=T...")
- 13:23, 20 June 2024 MKraft talk contribs created page Ota et al. (2014): The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study (Created page with "{{Reference |Reference=Publication: The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study }} =Brief summary= This study investigated the effect of vitamin B6 on chemotherapy side effects in patients with colorectal cancer. Half of the patients received a vitamin B6 preparation in addition to chemotherapy and the other half only chemotherapy. The two groups did not diff...")
- 13:22, 20 June 2024 MKraft talk contribs created page Publication: The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study (Created page with "{{Publication |Title=The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study |Topic=Vitamin B6 |Author=Sure, here is the list rewritten in the specified style: Ota, M.; Tatsumi, K.; Suwa, H.; Watanabe, J.; Watanabe, K.; Osada, S.; Tanaka, K.; Shoichi, F.; Ichikawa, Y.; Kunisaki, C.; Endo, I. |Year=2014 |Journal=Hepato-Gastroenterology |DOI=http://www.ncbi.nlm.nih.gov/pu...")
- 10:04, 19 June 2024 MKraft talk contribs created page Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial (Created page with "{{Reference |Reference=Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial }} =Brief summary= This study also investigated the effect of vitamin B6 on chemotherapy side effects in patients with different types of cancer. At the start of chemotherapy, half of the patients were given a vitamin B6 preparation and the other half a placebo. The two groups did not differ in terms of...")
- 09:40, 19 June 2024 MKraft talk contribs created page Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial (Created page with "{{Publication |Title=Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial |Topic=Vitamin B6 |Author=Yap, Y.; Kwok, L.; Syn, N.; Chay, W. Y.; Chia, J. W. K.; Tham, C. K.; Wong, N. S.; Lo, S. K.; Dent, R. A.; Tan, S.; Mok, Z. Y.; Koh, K. X.; Toh, H. C.; Koo, W. H.; Loh, M.; Ng, R. C. H.; Choo, S. P.; Soong, R. C. T. |Year=2017 |Journal=JAMA Oncology |DOI=https://doi.org/10.1001/jamaoncol.2017...")
- 07:46, 19 June 2024 MKraft talk contribs created page Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group (Created page with "{{Reference |Reference=Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group }} =Brief summary= This study primarily investigated the effect of vitamin B6 in bladder cancer patients on disease-free survival and the recurrence rate. In addition, tumor progression and overall survival were considered. Ther...")
- 07:44, 19 June 2024 MKraft talk contribs created page Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group (Created page with "{{Publication |Title=Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group |Topic=Vitamin B6 |Author=Newling, D; Robinson, M; Smith, P; Byar, D; Lockwood, R; Stevens, I; De Pauw, M; Sylvester, R |Year=1995 |Journal=European urology. |DOI=https://doi.org/10.1159/000475139 |Authors Abstract=This double-blind randomised pha...")
- 14:49, 18 June 2024 MKraft talk contribs created page Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy (Created page with "{{Reference |Reference=Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy }} =Brief summary= This study investigated the effect of vitamin B6 on chemotherapy side effects in patients with different types of cancer. At the start of chemotherapy, half of the patients were given a vitamin B6 preparation and the other half a placebo. The two groups did not differ in terms of the number of people with hand-foot syndrom...")
- 14:33, 18 June 2024 MKraft talk contribs created page Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy (Created page with "{{Publication |Title=Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy |Topic=Vitamin B6 |Author=Braik, T; Yim, B; Evans, A T; Kassem, M; Mullane, M; Lad, T; Hussein, L; Cleveland, B; McDunn, S |Year=2014 |Journal=PloS one |DOI=https://doi.org/10.12788/jcso.0017 |Authors Abstract=Background: Capecitabine is an oral fuoropyrimidine that is used to treat various malignancies. Hand-foot syndrome (HFS) is a dose-limiting toxicity...")
- 09:06, 14 June 2024 MKraft talk contribs created page Puri et al. (2010): Lycopene in treatment of high-grade gliomas: A pilot study (Created page with "{{Reference |Reference=Publication: Lycopene in treatment of high-grade gliomas: A pilot study }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusion criteria=? |N randomized=-999 |Analysis=? |Specifications on analyses=? |Countries of data collection=? |LoE=? |Outcome timeline=? }}...")
- 09:03, 14 June 2024 MKraft talk contribs created page Publication: Lycopene in treatment of high-grade gliomas: A pilot study (Created page with "{{Publication |Title=Lycopene in treatment of high-grade gliomas: A pilot study |Topic=Lycopene |Author=Puri, T.; Goyal, S.; Julka, P. K.; Nair, O.; Sharma, D. N.; Rath, G. K. |Year=2010 |Journal=Neurology India |DOI=https://doi.org/10.4103/0028-3886.60389 |Authors Abstract=Background: The therapeutic benefit of lycopene is well established for carcinoma prostate in various clinical trials and has been proposed for other malignancies including high-grade gliomas. Se...")
- 08:38, 12 June 2024 MKraft talk contribs created page Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA (Created page with "{{Reference |Reference=Publication: Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA }} =Brief summary= In this well-conducted study, prostate cancer patients were divided into one of three groups three weeks before their planned prostate removal or radiotherapy. The first group was to consume a minimum amount of tomato products daily, the second group was to additionally consume other products such as green tea, pomegranate and grape j...")
- 08:30, 12 June 2024 MKraft talk contribs created page Publication: Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA (Created page with "{{Publication |Title=Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA |Topic=Lycopene |Author=Paur, I.; Lilleby, W.; Bøhn, S. K.; Hulander, E.; Klein, W.; Vlatkovic, L.; Axcrona, K.; Bolstad, N.; Bjøro, T.; Laake, P.; Taskén, K. A.; Svindland, A.; Eri, L. M.; Brennhovd, B.; Carlsen, M. H.; Fosså, S. D.; Smeland, S. S.; Karlsen, A. S.; Blomhoff, R. |Year=2017 |Journal=Clinical Nutrition |DOI=https://doi.org/10.1016/j.clnu.2016.06.014...")
- 15:07, 11 June 2024 MKraft talk contribs created page Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients (Created page with "{{Reference |Reference=Publication: Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients }} =Brief summary= In this study, a large sample of 120 cancer patients who had received cisplatin chemotherapy was examined. Half of the patients received lycopene in addition to chemotherapy and standard treatment to prevent kidney damage. Neither the participants nor the study leaders knew who was also receiving lycopene. The values recorded to deter...")
- 14:56, 11 June 2024 MKraft talk contribs created page Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients (Created page with "{{Reference |Reference=Publication: Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients }} =Brief summary= In this study, a large sample of 120 cancer patients who had received cisplatin chemotherapy was examined. Half of the patients received lycopene in addition to chemotherapy and standard treatment to prevent kidney damage. Neither the participants nor the study leaders knew who was also receiving lycopene. The values recorded to deter...")
- 14:47, 11 June 2024 MKraft talk contribs created page Publication: Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients (Created page with "{{Publication |Title=Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients |Topic=Lycopene |Author=Mahmoodnia, L.; Mohammadi, K.; Masumi, R. |Year=2017 |Journal=Journal of nephropathology |DOI=https://doi.org/10.15171/jnp.2017.25 |Authors Abstract=Background: Nephrotoxicity is one of the most important limitations of cisplatin-based chemotherapies which associated with many complications and high mortality rate. Objectives: To investigate...")
- 14:10, 11 June 2024 MKraft talk contribs created page Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer (Created page with "{{Reference |Reference=Publication: Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer }} =Brief summary= This study compared three groups of patients, all of whom had prostate cancer and were on an active surveillance program. They were given a lycopene tablet (15mg), a fish oil tablet or a matching placebo twice a day for 3 months. The “prostate specific antigen” (PSA) is an important indicator of the development o...")
- 14:04, 11 June 2024 MKraft talk contribs created page Publication: Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer (Created page with "{{Publication |Title=Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer |Topic=Lycopene |Author=Chan, J.; Weinberg, V.; Magbanua, M.; Sosa, E.; Simko, J.; Shinohara, K.; Federman, S.; Mattie, M.; Hughes-Fulford, M.; Haqq, C.; Carroll, P. |Year=2011 |Journal=Cancer Causes Control |DOI=https://doi.org/10.1007/s10552-010-9684-5 |Authors Abstract=Background: Nutritional factors are associated with reduced risk of prostate ca...")
- 13:02, 2 June 2024 MKraft talk contribs created page Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study (Created page with "{{Reference |Reference=Publication: Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study }} =Brief summary= In the study, the data of 77 neoadjuvant patients or patients with metastatic breast cancer were analyzed. They were previously randomly divided into two groups, so that 40 patients followed an MKT-based ketogenic diet (high fat, low carbohydrate and additional intake of medium-chai...")
- 12:56, 2 June 2024 MKraft talk contribs created page Publication: Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study (Created page with "{{Publication |Title=Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study |Topic=Low-carbohydrate or ketogenic diet |Author=Khodabakhshi, A.; Akbari, M. E.; Mirzaei, H. R.; Mehrad-Majd, H.; Kalamian, M.; Davoodi, S. H. |Year=2019 |Journal=Nutrition and Cancer |DOI=https://doi.org/10.1080/01635581.2019.1650942 |Authors Abstract=The present study was aimed to evaluate the safety, tolerabili...")
- 09:03, 1 June 2024 MKraft talk contribs created page Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) (Created page with "{{Reference |Reference=Publication: A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusion criteria=? |N ra...")
- 09:00, 1 June 2024 MKraft talk contribs created page Publication: A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) (Created page with "{{Publication |Title=A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) |Topic=Low-carbohydrate or ketogenic diet |Author=Freedland, S. J.; Allen, J.; Jarman, A.; Oyekunle, T.; Armstrong, A. J.; Moul, J. W.; Sandler, H. M.; Posadas, E.; Levin, D.; Wiggins, E.; Howard, L. E.; Wu, Y.; Lin, P.-H. |Year=2020 |Journal=Clin Cancer Res |DOI=https://doi...")
- 07:01, 1 June 2024 MKraft talk contribs created page Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial (Created page with "{{Reference |Reference=Publication: Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial }} =Brief summary= =Study Design= {{Study Design (RCT) |Perspective=? |Centralized=? |Blinding=? |Is randomized=Yes |Cross-over=No |Number of arms=-999 }} =Study characteristics= {{RCT study general properties |Inclusion criteria=? |Exclusion criteria=? |N randomi...")
- 06:59, 1 June 2024 MKraft talk contribs created page Publication: Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial (Created page with "{{Publication |Title=Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial |Topic=Low-carbohydrate or ketogenic diet |Author=Cohen, C. W.; Fontaine, K. R.; Arend, R. C.; Soleymani, T.; Gower, B. A. |Year=2018 |Journal=Nutrients |DOI=10.3390/nu10091187 |Authors Abstract=Ketogenic diets (KDs) are gaining attention as a potential adjuvant therapy for cancer,...")
- 08:51, 24 May 2024 MKraft talk contribs created page Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study (Created page with "{{Reference |Reference=Publication: Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study }} =Brief summary= In this study, 48 patients with gynecological cancer were randomly divided into two groups. One group received a capsule containing 500mg of ginger powder four times a day from the first to the fifth day of chemotherapy, while the other group received a placebo. Both grou...")
- 08:44, 24 May 2024 MKraft talk contribs created page Publication: Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study (Created page with "{{Publication |Title=Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial |Topic=Ginger (also contains zerumbone) |Author=Uthaipaisanwong, A.; Oranratanaphan, S.; Musigavong, N. |Year=2020 |Journal=Supportive Care in Cancer |DOI=https://doi.org/10.1007/s00520-019-05201-5 |Authors Abstract=Purpose: To determine effects of ginger on red...")
- 14:32, 13 May 2024 MKraft talk contribs created page Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial (Created page with "{{Reference |Reference=Publication: Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial }} =Brief summary= In this study, 146 lung cancer patients undergoing chemotherapy were randomly divided into two groups. One group received a capsule containing 250 mg of ginger powder twice daily for 5 days from the start of chemotherapy, while...")
- 13:36, 13 May 2024 MKraft talk contribs created page Publication: Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial (Created page with "{{Publication |Title=Publication: Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial |Topic=Ginger (also contains zerumbone) |Author=Li, X.; Qin, Y.; Liu, W.; Zhou, X.; Li, Y.; Wang, L. |Year=2018 |Journal=Integrative cancer therapies |DOI=https://doi.org/10.1177/153473541775354 |Authors Abstract=Nausea and vomiting are among the mo...")